Clinical Trials Logo

Filter by:
NCT ID: NCT01322659 Completed - Clinical trials for Inadequate or Impaired Breathing Pattern or Ventilation

Weaning Using Noninvasive Positive Pressure Ventilation by Means of Helmet in Patients With Acute Respiratory Failure

Start date: March 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether helmet is effective as device for noninvasive positive pressure ventilation in the weaning from mechanical ventilation.

NCT ID: NCT01321554 Completed - Thyroid Cancer Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

SELECT
Start date: March 17, 2011
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).

NCT ID: NCT01321541 Completed - Clinical trials for Diffuse Large B-cell Lymphoma

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

PIX-R
Start date: April 20, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.

NCT ID: NCT01321450 Completed - Clinical trials for Chronic Pancreatitis

Economisation of Whipple Resection Using an Ultrasonic Dissection Device

Start date: March 2009
Phase:
Study type: Observational

Including 150 randomised patient, the studies aim is to determine whether an economisation and/or improvement in terms of operating time, drainage fluid, blood loss, time of hospitalisation can be found using an ultrasonic dissection device versus traditional surgical methods such as stitches an ligations.The study is performed for patients undergoing partial pancreatoduodenectomy.

NCT ID: NCT01321255 Completed - Clinical trials for Myocardial Infarction

Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

FOCUS
Start date: January 2012
Phase: Phase 3
Study type: Interventional

The aim of the FOCUS project is to test the Fixed Dose Combination concept for cardiovascular prevention in populations of different socio-economic characteristics. At the same time, FOCUS aims to understand the factors determining inappropriate prescribing for secondary cardiovascular prevention and those for poor patients adherence to treatment. This will allow FOCUS to establish recommendations for a better use of medication in patients with ischemic heart disease. In addition, after a successful completion of FOCUS, secondary prevention medication will be available and affordable for a large number of patients in both developed as well as developing countries. There are two Phases in this study: Phase 1: Is a descriptive, non interventional study. Phase 2: Is an interventional, randomized trial with prospective economic evaluation.

NCT ID: NCT01320891 Completed - Large Bowel Cancer Clinical Trials

Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators

Start date: February 2010
Phase: N/A
Study type: Interventional

Aim of the study is to ascertain whether a different strategy of fluids administration can be responsible of differences in terms of acid/base disorders (Stewart approach), pro-inflammatory and inflammatory mediators. Hence two groups of patients will be treated either with not-balanced solutions (Normal Saline) or balanced solutions

NCT ID: NCT01320085 Completed - Clinical trials for BRAF or NRAS Mutant Metastatic Melanoma

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Start date: March 24, 2011
Phase: Phase 2
Study type: Interventional

The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.

NCT ID: NCT01319487 Completed - Clinical trials for Diabetic Macular Edema

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment.

NCT ID: NCT01318941 Completed - Clinical trials for Diabetic Macular Edema

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

LUMINOUS
Start date: March 2011
Phase: N/A
Study type: Observational

This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.

NCT ID: NCT01318902 Completed - Clinical trials for Light-Chain Amyloidosis

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Start date: April 27, 2011
Phase: Phase 1
Study type: Interventional

This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.